Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
February 07 2023 - 8:00AM
Esperion (NASDAQ: ESPR) today announced it will report fourth
quarter and full year 2022 financial results before the open of the
U.S. financial markets on Tuesday, February 21, 2023.
Following the release, company management will host a webcast
and conference call at 8:00 a.m. ET to discuss the financial
results and upcoming corporate milestones. Please click here to
pre-register to participate in the conference call and obtain your
dial in number and PIN.
Already registered? Access with your PIN here.
A live webcast can be accessed on the investors and media
section of the Esperion website. Access to the webcast replay will
be available approximately two hours after completion of the call
and will be archived on the Company’s website for approximately 90
days.
Esperion TherapeuticsEsperion works hard to
make our medicines easy to get, easy to take, and easy to have. We
discover, develop, and commercialize innovative medicines and
combinations to lower cholesterol, especially for patients whose
needs aren’t being met by the status quo. Our entrepreneurial team
of industry leaders is inclusive, passionate and resourceful. We
are singularly focused on managing cholesterol so you can improve
your health easily. For more information, please visit esperion.com
and follow us on Twitter at www.twitter.com/EsperionInc.
Contact:Esperion Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024